Table 4.
Outcomes on IMRT for NPC
| Study (authors or trial) | N | Stage III/IV (%) (AJCC) | Time point (years) | OS (%) | LC (%) | RC (%) | DMFS (%) | Ref |
|---|---|---|---|---|---|---|---|---|
| Lee et al (UCSF) | 67 | 70 | 4 | 88 | 97 | 98 | 66 | 36 |
| Kam et al (Hong Kong) | 63 | 57 | 3 | 90 | 92 | 98 | 79 | 71 |
| Kwong et al (Hong Kong) | 33 | 3 | 3 | 100 | 100 | 92 | 100 | 38 |
| Wolden et al (MSKCC) | 74 | 77 | 3 | 83 | 91 | 93 | 78 | 35 |
| Lee et al (RTOG 02-25) | 68 | 59 | 2 | 80 | 93 | 91 | 85 | 39 |
| Tham et al (Singapore) | 195 | 63 | 3 | 94 | 90 | 89 | 72 | |
| Lin et al (Fujian) | 323 | 80 | 3 | 90 | 95 | 98 | 90 | 73 |
| Wong et al (Hong Kong) | 175 | 35 | 3 | 87 | 94 | 93 | 87 | 74 |
| Ng et al (Hong Kong) | 193 | 61 | 2 | 92 | 95 | 96 | 90 | 75 |
| Xiao et al (Guangzhou) | 81 | 100 | 5 | 75 | 95 | 76 | ||
| Lai et al (Guangzhou) | 512 | 52 | 5 | 93 | 97 | 84 | 77 |
Abbreviations: AJCC, American Joint Committee on Cancer; DMFS, distant metastasis-free survival. LC, local control; MSKCC, Memorial Sloan-Kettering Cancer Center; OS, overall survival; RC, regional control; RTOG, Radiation Therapy Oncology Group; UCSF, University of California San Francisco; IMRT, intensity-modulated radiation therapy; NPC, nasopharyndeal carcinoma.